Knowledge Management in Biotechnology Drugs in Brazil as a Case Study of the National Pharmaceuticals Laboratories

Biotechnology (Faisalabad, Pakistan) Pub Date : 2019-01-01 DOI:10.4018/978-1-5225-3012-1.CH033

J. Magalhães, M. D. Carmo, Z. Hartz

{"title":"Knowledge Management in Biotechnology Drugs in Brazil as a Case Study of the National Pharmaceuticals Laboratories","authors":"J. Magalhães, M. D. Carmo, Z. Hartz","doi":"10.4018/978-1-5225-3012-1.CH033","DOIUrl":null,"url":null,"abstract":"The informational age in the twenty-first century is also known as the age of knowledge. The great differential of organizations has been the strategic innovation through the best way to manage the existing knowledge. The pharmaceutical area is one of the most intensive areas in research, development, and innovation. In this century, the discovery of new drugs and biotechnology drugs has revolutionized several treatments for human health. It is estimated that in 2017 the medical prescriptions of biotech drugs will exceed US $220 billion. It was identified that by the year 2019, several biotechnological patents will be expired in the world. New structures and strategic innovations in the scientific and technological environment of the Brazilian pharmaceutical area have occurred. There is a boom in investment opportunities in the industry through strategic innovation fostered by the updating of Brazilian legislation and investments by private companies. Knowledge management in biotechnological drugs has favored scientific, technological, and market growth in Brazilian organizations.","PeriodicalId":93084,"journal":{"name":"Biotechnology (Faisalabad, Pakistan)","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology (Faisalabad, Pakistan)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4018/978-1-5225-3012-1.CH033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The informational age in the twenty-first century is also known as the age of knowledge. The great differential of organizations has been the strategic innovation through the best way to manage the existing knowledge. The pharmaceutical area is one of the most intensive areas in research, development, and innovation. In this century, the discovery of new drugs and biotechnology drugs has revolutionized several treatments for human health. It is estimated that in 2017 the medical prescriptions of biotech drugs will exceed US $220 billion. It was identified that by the year 2019, several biotechnological patents will be expired in the world. New structures and strategic innovations in the scientific and technological environment of the Brazilian pharmaceutical area have occurred. There is a boom in investment opportunities in the industry through strategic innovation fostered by the updating of Brazilian legislation and investments by private companies. Knowledge management in biotechnological drugs has favored scientific, technological, and market growth in Brazilian organizations.

查看原文本刊更多论文

巴西生物技术药物的知识管理——以国家药物实验室为例

21世纪的信息时代也被称为知识时代。组织的巨大差异在于通过对现有知识的最佳管理方式进行战略创新。制药领域是研究、开发和创新最密集的领域之一。在本世纪，新药物和生物技术药物的发现彻底改变了人类健康的几种治疗方法。据估计，2017年生物技术药物的医疗处方将超过2200亿美元。据确定，到2019年，全球将有几项生物技术专利到期。巴西制药领域的科技环境出现了新的结构和战略创新。巴西立法的更新和私营公司的投资促进了战略创新，该行业的投资机会激增。生物技术药物的知识管理有利于巴西组织的科学、技术和市场增长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology (Faisalabad, Pakistan)

自引率

0.00%

发文量